City

Clinical trials near Berlin, Germany

Active studies with a listed research site in Berlin, Germany.

21active studies

12recruiting now

27countries represented

188largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Obesity, OverweightCondition

Cagrilintide D, Cagrilintide B and placebo semaglutide ITreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-26 · NCT07597018See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Overweight, ObesityCondition

Cagrilintide, Placebo CagrilintideTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-15 · NCT07557953See eligibility →

Recruiting nowPhase 1

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-27 · NCT07508020See eligibility →

Recruiting nowNot applicable

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Monogenic ObesityCondition

Semaglutide (administered by PDS290 pen-injector)Treatment

France, Germany7 locations

Prof. Dr. Martin WabitschSponsor

Updated 2026-01-08 · NCT07302802See eligibility →

Recruiting nowNot applicable

Cohort Study on Plant-based Diets (COPLANT Study)

Dietary Exposure, Diabetes Mellitus, Type 2Condition

Intervention not listedTreatment

Austria, Germany8 locations

German Federal Institute for Risk AssessmentSponsor

Updated 2025-02-14 · NCT06323538See eligibility →

Recruiting nowNot applicable

The European NAFLD Registry

NAFLD, NASHCondition

Intervention not listedTreatment

Belgium, Finland37 locations

Newcastle UniversitySponsor

Updated 2023-01-06 · NCT04442334See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonNot applicable

Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity

Typ 2 Diabetes, ObesityCondition

endoscopic implantTreatment

Germany8 locations

Trans-Duodenal Concepts GmbHSponsor

Updated 2026-02-18 · NCT07417683See eligibility →

Active, not recruitingPhase 3

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Argentina, Bulgaria188 locations

PfizerSponsor

Updated 2026-09-08 · NCT07400653See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

Active, not recruitingNot applicable

Weight Loss Surgery in Adolescents With Extreme Obesity

Obesity, Extreme ObesityCondition

bariatric surgery, conservative careTreatment

Germany5 locations

Prof. Dr. Martin WabitschSponsor

Updated 2024-05-08 · NCT02062164See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Berlin, Germany

Current studies

Related cities